Integration of B-cell receptor-induced ERK1/2 phosphorylation and mutations of SF3B1 gene refines prognosis in treatment naive chronic lymphocytic leukemia.

Signaling events downstream of the B-cell receptor (BCR) are key determinants of the clinical behavior of chronic lymphocytic leukemia (CLL).[1][1],[2][2] Extracellular signal-regulated kinase 1/2 (ERK1/2) is a major pathway downstream of BCR stimulation.[3][3],[4][4] In a recent study, applying a